Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 200 of 360

Type: Guidance`Remove $Type: Guidance filter`

Guidance and quality standards awaiting development
Title	Type
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]	Technology appraisal guidance
Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]	Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication	HealthTech guidance
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]	Technology appraisal guidance
Laroprovstat for treating primary hypercholesterolaemia or mixed dyslipidaemia disease [TSID12430]	Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance
Lemborexan for treating insomnia [GID-TA12011]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]	Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]	Technology appraisal guidance
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]	Technology appraisal guidance
Lotilaner for treating moderate to severe demodex blepharitis [TSID12419]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Luspatercept for treating haemoglobin H disease [ID6714]	Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]	Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]	Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]	Technology appraisal guidance
Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]	Technology appraisal guidance
Miniature lens system implantation for advanced age-related macular degeneration	HealthTech guidance
MK-3000 for treating diabetic macular oedema [TSID12422]	Technology appraisal guidance
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Nemtabrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma without a 17p deletion or TP53 mutation [TSID12404]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]	Technology appraisal guidance
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance

Results per page

10
25
50
All